US OptionsDetailed Quotes
UTHR241220C320000
- 39.60
- 0.000.00%
15min DelayTrading Dec 20 16:00 ET
0.00High0.00Low
0.00Open39.60Pre Close0 Volume0 Open Interest320.00Strike Price0.00Turnover0.00%IV0.68%PremiumDec 20, 2024Expiry Date37.18Intrinsic Value100Multiplier-10DDays to Expiry2.42Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma9.02Leverage Ratio--Theta--Rho--Eff Leverage--Vega
United Therapeutics Stock Discussion
Sign in to post a comment
$United Therapeutics (UTHR.US)$ free Luigi
1
I’m buying these 5 stocks! I’ll show you what convinced me to buy these compaines, plus how many shares i bought, and how much im up/down on them!
$Nike (NKE.US)$ $Hershey (HSY.US)$ $Yelp Inc (YELP.US)$ $Constellation Energy (CEG.US)$ $United Therapeutics (UTHR.US)$
$Nike (NKE.US)$ $Hershey (HSY.US)$ $Yelp Inc (YELP.US)$ $Constellation Energy (CEG.US)$ $United Therapeutics (UTHR.US)$
From YouTube
2
$United Therapeutics (UTHR.US)$
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting | UTHR Stock News
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting | UTHR Stock News
$United Therapeutics (UTHR.US)$
lol that is a shit ton of inside selling all at the end of June
lol that is a shit ton of inside selling all at the end of June
$United Therapeutics (UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3 ...
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3 ...
19
2
2
$Travere Therapeutic (TVTX.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...
$CG Oncology (CGON.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...
20
4
Are you a high net profit margin lover? So you will like these 1⃣2⃣ stocks with a net profit margin above 4⃣0⃣%
🇺🇸 Texas Pacific Land $Texas Pacific Land (TPL.US)$ 63.3%
🇸🇪 Evolution $Evotec (EVO.US)$ 59.3%
🇺🇸 CME Group $CME Group (CME.US)$ 57.1%
🇺🇸 Visa $Visa (V.US)$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR (RTMVY.US)$ 54.8%
🇺🇸 Verisign $VeriSign (VRSN.US)$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise (PME.US)$ 49.8%
🇺🇸 NVidia $NVIDIA (NVDA.US)$ 47.3%
🇺🇸 Mastercard $MasterCard (MA.US)$ 45.1%
🇫🇷 GTT $GTT Communications, Inc. (GTTN.US)$ 44.8% ...
🇺🇸 Texas Pacific Land $Texas Pacific Land (TPL.US)$ 63.3%
🇸🇪 Evolution $Evotec (EVO.US)$ 59.3%
🇺🇸 CME Group $CME Group (CME.US)$ 57.1%
🇺🇸 Visa $Visa (V.US)$ 55.3%
🇬🇧 Rightmove $RIGHTMOVE ADR (RTMVY.US)$ 54.8%
🇺🇸 Verisign $VeriSign (VRSN.US)$ $50.1%
🇦🇺 Pro Medicus $Pingtan Marine Enterprise (PME.US)$ 49.8%
🇺🇸 NVidia $NVIDIA (NVDA.US)$ 47.3%
🇺🇸 Mastercard $MasterCard (MA.US)$ 45.1%
🇫🇷 GTT $GTT Communications, Inc. (GTTN.US)$ 44.8% ...
14
The low P/E despite solid growth numbers seems to stem from investor sentiment, possibly from certain unobserved threats affecting the stock. Some shareholders might be skeptical of the earnings forecasts, indicating potential earnings instability.
United Therapeutics' strong financials could suggest long-term stock increase. Its net income growth might be due to good management and a low payout ratio, even though the earnings growth may slow down in future.
No comment yet
長崎 そよ : A stock that doesn't move at all.